Schwab Charles Investment Management Inc. boosted its stake in shares of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) by 22.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 209,273 shares of the biopharmaceutical company’s stock after buying an additional 38,123 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Alder BioPharmaceuticals were worth $4,353,000 as of its most recent filing with the SEC.

Several other large investors have also recently added to or reduced their stakes in the stock. Citadel Advisors LLC raised its position in shares of Alder BioPharmaceuticals by 1,209.4% in the first quarter. Citadel Advisors LLC now owns 467,387 shares of the biopharmaceutical company’s stock valued at $9,722,000 after buying an additional 431,691 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Alder BioPharmaceuticals during the first quarter valued at about $564,000. Geode Capital Management LLC raised its position in shares of Alder BioPharmaceuticals by 21.4% in the first quarter. Geode Capital Management LLC now owns 401,570 shares of the biopharmaceutical company’s stock valued at $8,352,000 after buying an additional 70,691 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Alder BioPharmaceuticals by 6.0% in the first quarter. Vanguard Group Inc. now owns 3,438,702 shares of the biopharmaceutical company’s stock valued at $71,524,000 after buying an additional 194,185 shares in the last quarter. Finally, Marshall Wace North America L.P. bought a new position in shares of Alder BioPharmaceuticals during the first quarter valued at about $4,450,000. 78.83% of the stock is currently owned by institutional investors.

Shares of Alder BioPharmaceuticals, Inc. (NASDAQ ALDR) traded down 1.344% during mid-day trading on Monday, reaching $9.175. The company had a trading volume of 214,030 shares. The company’s market capitalization is $621.27 million. The firm has a 50-day moving average of $11.56 and a 200-day moving average of $18.22. Alder BioPharmaceuticals, Inc. has a 12-month low of $8.80 and a 12-month high of $36.48.

Alder BioPharmaceuticals (NASDAQ:ALDR) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.67) by $0.19. The company had revenue of $0.68 million during the quarter. During the same period in the prior year, the firm posted ($0.79) earnings per share. Alder BioPharmaceuticals’s quarterly revenue was up 518.2% compared to the same quarter last year. On average, equities analysts anticipate that Alder BioPharmaceuticals, Inc. will post ($5.82) earnings per share for the current fiscal year.

WARNING: “Schwab Charles Investment Management Inc. Purchases 38,123 Shares of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/schwab-charles-investment-management-inc-purchases-38123-shares-of-alder-biopharmaceuticals-inc-nasdaqaldr/1486991.html.

Several research analysts recently issued reports on ALDR shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $43.00 target price on shares of Alder BioPharmaceuticals in a research report on Monday, April 17th. Aegis reissued a “buy” rating and issued a $41.00 price objective on shares of Alder BioPharmaceuticals in a research report on Tuesday, April 25th. UBS AG initiated coverage on Alder BioPharmaceuticals in a research report on Friday, May 5th. They issued a “sell” rating and a $13.00 price objective for the company. Needham & Company LLC initiated coverage on Alder BioPharmaceuticals in a research report on Monday, May 15th. They issued a “buy” rating and a $36.00 price objective for the company. Finally, Leerink Swann reissued an “outperform” rating and issued a $32.00 price objective on shares of Alder BioPharmaceuticals in a research report on Monday, June 12th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $32.92.

In other Alder BioPharmaceuticals news, Director Stephen M. Dow bought 25,000 shares of the firm’s stock in a transaction on Tuesday, July 18th. The stock was acquired at an average price of $10.00 per share, with a total value of $250,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 10.60% of the stock is owned by corporate insiders.

Alder BioPharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Want to see what other hedge funds are holding ALDR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR).

Institutional Ownership by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.